# US 9,707,251 B2 · Siloxane-based artificial blockage to control bleeding

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,707,251 B2
- Document ID: US9707251B2
- Status: Granted
- Kind: B2
- Application number: 13/584,852
- Filed: 2012-08-14
- Published: 2012-12-06
- Granted: 2017-07-18
- Earliest claimed: 2008-03-11
- Assignees: Materials Modification, Inc.
- Applicants: Kausik Mukhopadhyay; Krishnaswamy Kasthuri Rangan; Tirumalai Srinivas Sudarshan
- Inventors: Kausik Mukhopadhyay; Krishnaswamy Kasthuri Rangan; Tirumalai Srinivas Sudarshan
- Web page: https://patentgrep.com/patent/US9707251B2

## CPC

- A61K 31/74: Synthetic polymeric materials
- A61K 31/80: Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
- A61L 15/425: {Porous materials, e.g. foams or sponges}
- A61L 24/001: {Use of materials characterised by their function or physical properties}
- A61L 24/0015: {Medicaments; Biocides}
- A61L 24/0089: {containing inorganic fillers not covered by groups A61L24/0078 or A61L24/0084}
- A61L 26/0009: {containing macromolecular materials}
- A61L 26/0085: {Porous materials, e.g. foams or sponges}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61L 2300/11: Peroxy compounds, peroxides, e.g. hydrogen peroxide
- A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents
- A61L 2400/04: Materials for stopping bleeding
- A61L 2400/06: Flowable or injectable implant compositions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Two siloxane-based mixtures combine to form a soft or semi-solid matrix for forming an artificial blockage to control bleeding, particularly moderate to severe bleeding. The first component includes a homogeneous mixture or solution that includes a polymeric matrix, a surfactant, filler(s) and metal compound(s). The second component includes a homogeneous mixture or solution that includes a polymer(s), a filler(s), a surfactant, and hydrogen peroxide. The combination of the two components is carried out with adequate mixing using mechanical and micro-kinetic mixing mechanisms and can be performed in a field-ready delivery device.

## Claims

### Claim 1

A two-fluid component injection device for in situ formation of a soft solid artificial blockage to control moderate to severe bleeding, the two-fluid component injection device comprising two isolated chambers, wherein the two isolated chambers comprise a first isolated chamber and a second isolated chamber, the two-fluid component injection device comprising:
a) the first isolated chamber comprising a first fluid component, the first fluid component comprising:
i) about 75-90% by weight or volume of at least one siloxane polymer;
ii) about 0.5-25% by weight or volume of at least one siloxane polymer curing agent;
iii) about 12-18% by weight or volume of a metal mixture selected from the group consisting of 1) calcium oxide and iron oxides, and, 2) calcium hydroxide and iron oxides; and,
iv) about 0-25% of a surfactant;
b) the second isolated chamber comprising a second fluid component, the second fluid component comprising:
i) about 75-85% by weight or volume of at least one siloxane polymer;
ii) about 1-20% by weight or volume of hydrogen peroxide;
iii) about 0-25% of a surfactant;
wherein the device comprises a mixing tip for mixing the first fluid component and the second fluid component in the two-fluid component injection device to form an active hemostatic dressing, the active hemostatic dressing being injectable into a wound to form the soft solid artificial blockage within the wound,
wherein the first fluid component and the second fluid component are kept separately within the two isolated chambers of the two-fluid component injection device until mixed within the mixing tip for application into the wound,
wherein the iron oxides in the mixture function as negative co-catalysts in the decomposition of hydrogen peroxide,
wherein the siloxane polymer curing agent in the first fluid component is selected from the group consisting of platinum, tin, palladium, rhodium, and respective compounds, salts, complexes thereof, and a combination thereof,
wherein the soft solid artificial blockage conforms to irregular wound surfaces, and the hydrogen peroxide in the soft solid artificial blockage is less than 5% by weight or volume.

### Claim 2 (depends on 1)

The two-fluid component injection device of claim 1, wherein the siloxane polymer curing agent in said first fluid component is present at about 0.5-3% by weight or volume.

### Claim 3 (depends on 1)

The two-fluid component injection device of claim 1, wherein the hydrogen peroxide in said second fluid component comprises about 5-18% by weight or volume.

### Claim 4 (depends on 1)

The two-fluid component injection device of claim 1, wherein said second fluid component further comprises about 0-10% by weight or volume of a particle filler.

### Claim 5 (depends on 4)

The two-fluid component injection device of claim 4, wherein the particle filler in said second fluid component comprises at least one member selected from the group consisting of silicon oxide, fumed silica, titanium dioxide, diatomaceous earth, calcium silicate, aluminum silicate, zeolite, mesoporous material, clay, polyhedral oligomeric silsesquioxane, a chemical and functional derivative of polyhedral oligomeric silsesquioxane, and a combination thereof.

### Claim 6

A two-fluid component injection device for in situ formation of a soft solid artificial blockage to control moderate to severe bleeding, the two-fluid component injection device comprising two isolated chambers, wherein the two isolated chambers comprise a first isolated chamber and a second isolated chamber, the two-fluid component injection device comprising:
a) the first isolated chamber comprising a first fluid component, the first fluid component comprising:
i) about 84% by weight or volume of at least one siloxane polymer;
ii) about 0.5-2% by weight or volume of at least one surfactant;
iii) about 0.5-3% by weight or volume of at least one siloxane polymer curing agent; and
iv) about 12-18% by weight or volume of a metal mixture selected from the group consisting of 1) calcium oxide and iron oxides, and, 2) calcium hydroxide and iron oxides;
b) the second isolated chamber comprising a second fluid component, the second fluid component comprising:
i) about 82% by weight or volume of at least one siloxane polymer;
ii) about 0.5-2% by weight or volume of at least one surfactant;
iii) about 17.5% by weight or volume of hydrogen peroxide; and
iv) about 0.2% by weight or volume of at least one particle filler.

### Claim 7

A soft solid hemostatic blockage composition formed in situ by using a two-fluid component injection device to control moderate to severe bleeding, the two-fluid component injection device comprising two isolated chambers, wherein the two isolated chambers comprise a first isolated chamber and a second isolated chamber, the two-fluid component injection device comprising:
a) the first isolated chamber comprising a first fluid component, the first fluid component comprising:
i) about 75-90% by weight or volume of at least one siloxane polymer;
ii) about 0-25% by weight or volume of at least one surfactant;
iii) about 0.5-25% by weight or volume of at least one siloxane polymer curing agent; and
iv) about 12-18% by weight or volume of a metal mixture selected from the group consisting of 1) calcium oxide and iron oxides, and, 2) calcium hydroxide and iron oxides;
b) the second isolated chamber comprising a second fluid component, the second fluid component comprising:
i) about 75-85% by weight or volume of at least one siloxane polymer;
ii) about 0-25% by weight or volume of at least one surfactant;
iii) about 1-20% by weight or volume of hydrogen peroxide; and
iv) about 0-10% by weight or volume of at least one particle filler, wherein the soft solid hemostatic blockage composition conforms to irregular wound surfaces.

### Claim 8

A soft solid hemostatic blockage composition formed in situ by using a two-fluid component injection device to control moderate to severe bleeding, the two-component injection device comprising two isolated chambers, wherein the two isolated chambers comprise a first isolated chamber and a second isolated chamber, the two-fluid component injection device comprising:
a) the first isolated chamber comprising a first fluid component, the first fluid component comprising:
i) about 84% by weight or volume of at least one siloxane polymer;
ii) about 0.5-2% by weight or volume of at least one surfactant;
iii) about 0.5-3% by weight or volume of at least one siloxane polymer curing agent; and
iv) about 12-18% by weight or volume of a metal mixture selected from the group consisting of 1) calcium oxide and iron oxides, and, 2) calcium hydroxide and iron oxides;
b) the second isolated chamber comprising a second fluid component, the second fluid component comprising:
i) about 82% by weight or volume of at least one siloxane polymer;
ii) about 0.5-2% by weight or volume of at least one surfactant;
iii) about 17.5% by weight or volume of hydrogen peroxide; and
iv) about 0.2% by weight or volume of at least one particle filler, wherein the soft solid hemostatic blockage composition conforms to irregular wound surfaces.

### Claim 9

A method for in situ formation of a soft solid artificial blockage in a wound or body cavity to control moderate to severe bleeding, comprising injecting from a two-fluid component injection device into the wound or body cavity, a composition that forms a soft solid artificial blockage within the wound, the two-fluid component injection device comprising two isolated chambers, wherein the two isolated chambers comprise a first isolated chamber and a second isolated chamber, the two-fluid component injection device comprising:
a) the first isolated chamber comprising a first fluid component, the first fluid component comprising:
i) about 75-90% by weight or volume of at least one siloxane polymer;
ii) about 0.5-25% by weight or volume of at least one siloxane polymer curing agent;
iii) about 12-18% by weight or volume of a metal mixture selected from the group consisting of 1) calcium oxide and iron oxides, 2) calcium hydroxide and iron oxides; and,
iv) about 0-25% of a surfactant;
b) the second isolated chamber comprising a second fluid component, the second fluid component comprising:
i) about 75-85% by weight or volume of at least one siloxane polymer;
ii) about 1-20% by weight or volume of hydrogen peroxide;
iii) about 0-25% by weight or volume of a surfactant;
wherein the injecting comprises mixing the first and second fluid components within a mixing tip in the two-fluid component injection device to form an active hemostatic dressing, the active hemostatic dressing being injectable into the wound to form the soft solid artificial blockage within the wound,
wherein the first fluid component and the second fluid component are kept separately within the two isolated chambers of the two-fluid injection device until mixed within the mixing tip for application into the wound,
wherein the iron oxides in the mixture function as negative co-catalysts in the decomposition of hydrogen peroxide,
wherein the siloxane polymer curing agent in the first fluid component is selected from the group consisting of platinum, tin, palladium, rhodium, and respective compounds, salts, complexes thereof, and a combination thereof,
wherein the soft solid artificial blockage conforms to irregular wound surfaces, and the hydrogen peroxide in the soft solid artificial blockage is less than 5% by weight or volume; and
allowing the composition to penetrate the wound or body cavity and expand therein to form a soft solid artificial blockage within the wound, and wherein the hydrogen peroxide in the soft solid artificial blockage is less than 5% by weight or volume.

### Claim 10 (depends on 9)

The method of claim 9, wherein mixing within the mixing tip comprises mechanical or micro-kinetic mixing, or a combination thereof.

### Claim 11 (depends on 9)

The method of claim 9, wherein the soft solid artificial blockage is substantially set in about 0 to 60 minutes.

### Claim 12 (depends on 9)

The method of claim 9, wherein the soft solid artificial blockage is substantially cross-linked and cured in less than 300 seconds.

### Claim 13 (depends on 9)

The method of claim 9, wherein the soft solid artificial blockage has an expansion volume of about 150-800%.

### Claim 14 (depends on 1)

The two-fluid component injection device of claim 1, wherein mixing the first component and the second component results in at least 2 times expansion in situ.

### Claim 15 (depends on 1)

The two-fluid component injection device of claim 1, wherein the hydrogen peroxide is completely reacted after mixing of the first component and the second component.

### Claim 16 (depends on 1)

The two-fluid component injection device of claim 1, wherein the second component comprises about 8.5% by weight or volume of hydrogen peroxide.

### Claim 17 (depends on 1)

The two-fluid component injection device of claim 1, wherein the artificial blockage comprises about 5% hydrogen peroxide.

### Claim 18 (depends on 1)

The two-fluid component injection device of claim 1, wherein mixing the first component and the second component results in temperature below 123° F.

### Claim 19 (depends on 1)

The two-fluid component injection device of claim 1, wherein the first fluid component comprises about 0.5-2% by weight or volume of at least one surfactant.

### Claim 20 (depends on 1)

The two-fluid component injection device of claim 1, wherein the second fluid component comprises about 0.5-2% by weight or volume of at least one surfactant.

### Claim 21 (depends on 1)

The two-fluid component injection device of claim 1, wherein the surfactant of the first fluid component comprises at least one member selected from the group consisting of polyether, polyol-polyether mixture, fluoro surfactant, fluoro surfactant and polyether polymer, nonylphenoxypoly(ethylene oxy)ethanol, polyoxyethylene sorbitan monolaurate, polyoxythylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, and a combination thereof.

### Claim 22 (depends on 1)

The two-fluid component injection device of claim 1, wherein the surfactant of the second fluid component comprises at least one member selected from the group consisting of polyether, polyol-polyether mixture, fluoro surfactant, fluoro surfactant and polyether polymer, polyoxyethylene sorbitan monolaurate, polyoxythylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, and a combination thereof.

### Claim 23 (depends on 1)

The two-fluid component injection device of claim 1,
wherein the siloxane polymer of the first fluid component is selected from the group consisting of poly(dimethylsiloxane) vinyl terminated, polydimethylsiloxane (PDMS), divinyltetramethyldisiloxane, and, di methylsiloxane, and,
wherein the siloxane polymer of the second fluid component is selected from the group consisting of poly(dimethylsiloxane) vinyl terminated, polydimethylsiloxane (PDMS), divinyltetramethyldisiloxane, methylhydrosiloxane, dimethylsiloxane, and, methylhydrosiloxane-dimethylsiloxane copolymer.

### Claim 24 (depends on 6)

The two-fluid component injection device of claim 6,
wherein the siloxane polymer of the first fluid component is selected from the group consisting of poly(dimethylsiloxane) vinyl terminated, polydimethylsiloxane (PDMS), divinyltetramethyldisiloxane, and, dimethylsiloxane, and,
wherein the siloxane polymer of the second fluid component is selected from the group consisting of poly(dimethylsiloxane) vinyl terminated, polydimethylsiloxane (PDMS), divinyltetramethyldisiloxane, methylhydrosiloxane, dimethylsiloxane, and, methylhydrosiloxane-dimethylsiloxane copolymer.

### Claim 25 (depends on 7)

The two-fluid component injection device of claim 7,
wherein the siloxane polymer of the first fluid component is selected from the group consisting of poly(dimethylsiloxane) vinyl terminated, polydimethylsiloxane (PDMS), divinyltetramethyldisiloxane, and, dimethylsiloxane, and,
wherein the siloxane polymer of the second fluid component is selected from the group consisting of poly(dimethylsiloxane) vinyl terminated, polydimethylsiloxane (PDMS), divinyltetramethyldisiloxane, methylhydrosiloxane, dimethylsiloxane, and, methylhydrosiloxane-dimethylsiloxane copolymer.

### Claim 26 (depends on 8)

The two-fluid component injection device of claim 8,
wherein the siloxane polymer of the first fluid component is selected from the group consisting of poly(dimethylsiloxane) vinyl terminated, polydimethylsiloxane (PDMS), divinyltetramethyldisiloxane, and, dimethylsiloxane, and,
wherein the siloxane polymer of the second fluid component is selected from the group consisting of poly(dimethylsiloxane) vinyl terminated, polydimethylsiloxane (PDMS), divinyltetramethyldisiloxane, methylhydrosiloxane, dimethylsiloxane, and, methylhydrosiloxane-dimethylsiloxane copolymer.

### Claim 27 (depends on 9)

The method of claim 9,
wherein the siloxane polymer of the first fluid component is selected from the group consisting of poly(dimethylsiloxane) vinyl terminated, polydimethylsiloxane (PDMS), divinyltetramethyldisiloxane, and, dimethylsiloxane, and,
wherein the siloxane polymer of the second fluid component is selected from the group consisting of poly(dimethylsiloxane) vinyl terminated, polydimethylsiloxane (PDMS), divinyltetramethyldisiloxane, methylhydrosiloxane, dimethylsiloxane, and, methylhydrosiloxane-dimethylsiloxane copolymer.

### Claim 28 (depends on 1)

The two-fluid component injection device of claim 1,
wherein the soft solid artificial blockage has a durometer reading of hardness on a scale of “OOO”.

### Claim 29 (depends on 28)

The two-fluid component injection device of claim 28,
wherein the durometer reading is 32 on a scale of “OOO”.